Spots Global Cancer Trial Database for A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
Official Title: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma
Study ID: NCT04814108
Conditions
Interventions
Study Description
Brief Summary: This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Detailed Description: This is a Phase 2 open-label, multicenter study to evaluate the clinical activity and safety of ZN-c3 (also known as azenosertib; KP-2638) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Alaska Women's Cancer Care, Anchorage, Alaska, United States
Honor Health, Phoenix, Arizona, United States
Arizona Oncology Associates Wilmot HOPE, Tucson, Arizona, United States
University of California Irvine Medical Center, Orange, California, United States
University of California San Francisco at Mission Bay, San Francisco, California, United States
Mount Sinai Medical Center, Miami Beach, Florida, United States
Sarasota Memorial Hospital, Sarasota, Florida, United States
University of South Florida, Tampa, Florida, United States
Northside Hospital, Atlanta, Georgia, United States
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
Maryland Oncology Hematology, Annapolis, Maryland, United States
University of Maryland Medical Center, Baltimore, Maryland, United States
Corewell Health, Grand Rapids, Michigan, United States
Revive Clinical Research, Sterling, Michigan, United States
HCA Midwest Health Kansas City Research, Kansas City, Missouri, United States
Center of Hope, Reno, Nevada, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Optimum Clinical Research Group- Women's Oncology, Albuquerque, New Mexico, United States
Westchester Medical Center, Hawthorne, New York, United States
University of Cincinnati, Cincinnati, Ohio, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
Trihealth Cancer Institute, Cincinnati, Ohio, United States
Ohio State University James Cancer Hospital, Columbus, Ohio, United States
University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Willamette Valley Cancer Institute, Eugene, Oregon, United States
Providence Portland Medical Center, Portland, Oregon, United States
Northwest Cancer Specialists, Portland, Oregon, United States
Temple University Hospital, Philadelphia, Pennsylvania, United States
Ascension St. Thomas Midtown Hospital, Nashville, Tennessee, United States
Texas Oncology Austin, Austin, Texas, United States
Texas Oncology Fort Worth Cancer Center, Fort Worth, Texas, United States
Texas Oncology Gulf Coast, Houston, Texas, United States
Texas Oncology San Antonio, San Antonio, Texas, United States
University of Virginia Cancer Center, Charlottesville, Virginia, United States
VCU Health System, Richmond, Virginia, United States
Virginia Cancer Specialists, Warrenton, Virginia, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Concord Repatriation General Hospital, Concord, New South Wales, Australia
Northern Cancer Institute, St Leonards, New South Wales, Australia
Icon Cancer Centre- Chermside, Brisbane, Queensland, Australia
Mater Cancer Care Centre, Mater Misericordiae Limited, Brisbane, Queensland, Australia
Burnside War Memorial Hospital, Toorak Gardens, South Australia, Australia
Cabrini Hospital Malvern, Malvern, Victoria, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Chu de Quebec-Universite, Quebec City, Quebec, Canada
Rustavi Clinic, Rustavi, Kvemo Kartli, Georgia
LTD High Technology Hospital Medcenter, Batumi, Republic Of Adjara, Georgia
Acad. Fridon Todua Medical Center, Tbilisi, , Georgia
LTD Innova Medical Center, Tbilisi, , Georgia
LTD TIM-Tbilisi Innova of Medicine, Tbilisi, , Georgia
Contact Details
Name: Project Director
Affiliation: K-Group Beta (A wholly owned subsidiary of Zentalis Pharmaceuticals)
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
